Meredith Cook Sells 500 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 500 shares of ANI Pharmaceuticals stock in a transaction dated Monday, July 13th. The stock was sold at an average price of $81.84, for a total value of $40,920.00. Following the completion of the transaction, the vice president owned 77,390 shares in the company, valued at approximately $6,333,597.60. This represents a 0.64% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Meredith Cook also recently made the following trade(s):

• On Friday, June 12th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $82.03, for a total value of $41,015.00.
• On Wednesday, May 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $78.16, for a total value of $39,080.00.

ANI Pharmaceuticals Trading Down 0.7%

ANIP traded down $0.53 on Tuesday, hitting $80.55. 228,925 shares of the company were exchanged, compared to its average volume of 385,099. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.12. The firm has a fifty day simple moving average of $81.62 and a two-hundred day simple moving average of $79.51. The stock has a market capitalization of $1.83 billion, a PE ratio of 20.39 and a beta of 0.43. ANI Pharmaceuticals, Inc. has a 12 month low of $62.60 and a 12 month high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.77. The firm had revenue of $237.46 million during the quarter, compared to the consensus estimate of $207.63 million. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The business’s revenue was up 20.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.70 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Sell-side analysts expect that ANI Pharmaceuticals, Inc. will post 8.03 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. Weiss Ratings raised shares of ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, June 23rd. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Guggenheim reaffirmed a “buy” rating and set a $124.00 price objective on shares of ANI Pharmaceuticals in a research note on Friday. Finally, Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Six investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $107.33.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Advisors Asset Management Inc. bought a new stake in ANI Pharmaceuticals in the first quarter worth $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of ANI Pharmaceuticals by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company’s stock valued at $736,000 after acquiring an additional 470 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of ANI Pharmaceuticals by 0.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company’s stock worth $3,235,000 after purchasing an additional 423 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of ANI Pharmaceuticals in the 1st quarter worth about $2,706,000. Finally, Norges Bank bought a new position in ANI Pharmaceuticals in the 2nd quarter worth about $625,000. Institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.